K
v
ire
.com
←
Back
Night
Docs
Library
Review
…
Author
Hartmut Schmidt
also known as H H J Schmidt, H H Schmidt, H H-J Schmidt
University Hospital Münster · Essen University Hospital · University of Duisburg-Essen · Université Paris-Sud
About this author
Works
1,030
Cited by
21,632
h-index
61
i10
248
ORCID ↗
Top papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams, Alejandra González‐Duarte, William O’Riordan, et al.
·
2018
·
New England Journal of Medicine
↗ 2,866
OA
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson, Márcia Waddington‐Cruz, John L. Berk, et al.
·
2018
·
New England Journal of Medicine
↗ 1,401
OA
Tafamidis for transthyretin familial amyloid polyneuropathy
Teresa Coelho, Luı́s F. Maia, Ana Silva, et al.
·
2012
·
Neurology
↗ 790
OA
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy
Sue Shackleton, David J. Lloyd, Stephen N.J. Jackson, et al.
·
2000
·
Nature Genetics
↗ 699
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial
Rafael Bañares, Frederik Nevens, Fin Stolze Larsen, et al.
·
2012
·
Hepatology
↗ 557
OA
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
Georg M. N. Behrens, André Dejam, Hartmut Schmidt, et al.
·
1999
·
AIDS
↗ 526
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis
Morie A. Gertz, Merrill D. Benson, P. James B. Dyck, et al.
·
2015
·
Journal of the American College of Cardiology
↗ 471
OA
Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review
Anton Gillessen, Hartmut Schmidt
·
2020
·
Advances in Therapy
↗ 464
OA
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis
Jonas Rosendahl, Heiko Witt, Richárd Szmola, et al.
·
2007
·
Nature Genetics
↗ 433
OA
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, et al.
·
2023
·
The Lancet Oncology
↗ 400
OA
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho, Luı́s F. Maia, Ana Silva, et al.
·
2013
·
Journal of Neurology
↗ 336
OA
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Ole B. Suhr, Teresa Coelho, Juan Buades, et al.
·
2015
·
Orphanet Journal of Rare Diseases
↗ 322
OA
Books
Advantages and disadvantages of an integrated market compared with a fragmented market
1977
·
Office for Official Publications of the European Communities
Zwischen Riga und Locarno
2000
·
Wichern-Verlag